(Q37961824)

26 August 2017

title

Novel oral anticoagulants and their role in clinical practice (English)

1 reference

26 August 2017

1 reference

1 reference

Ann K Wittkowsky

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

volume

31

1 reference

26 August 2017

issue

12

1 reference

26 August 2017

page(s)

1175-1191

1 reference

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Direct and indirect costs of management of long-term warfarin therapy in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Apixaban metabolism and pharmacokinetics after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Nonadherence in outpatient thromboprophylaxis after major orthopedic surgery: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

The importance of appropriate prophylaxis for the prevention of venous thromboembolism in at-risk medical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Oral rivaroxaban for symptomatic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Validation of Clinical Classification Schemes for Predicting Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Apixaban in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

New oral antithrombotics: a need for laboratory monitoring. Against

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Functional interaction of intestinal CYP3A4 and P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Warfarin dosing in patients with impaired kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Kidney function influences warfarin responsiveness and hemorrhagic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

Cytochrome P4502C9 activity in end‐stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.1175

21 January 2018

Identifiers

DOI

10.1592/PHCO.31.12.1175

1 reference

26 August 2017

1 reference